BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. -- (BUSINESS WIRE) -- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Richard A. Lewis, M.D., has been appointed as chair of Aerie’s Scientific Advisory Board, replacing David L. Epstein, M.D. Dr. Lewis’ appointment at Aerie is effective immediately.
“Dr. Lewis has an accomplished career as an esteemed clinical researcher and clinician, including in his own practice, and has held prominent leadership roles in the field of ophthalmology,” said Vicente Anido, Ph.D., Aerie’s Chairman and Chief Executive Officer. “We are very pleased that he will now assume the chairmanship of our SAB, further contributing to the advancement of Aerie’s clinical programs.”
Dr. Anido continued, “Dr. Lewis replaces Dr. David Epstein, who had been an integral part of our success. David unexpectedly passed away recently, and we are greatly saddened by the loss of a great friend, colleague and mentor. Our sympathies are with his family.”
Dr. Lewis is the former director of glaucoma at the University of California, Davis. In addition to his clinical practice, Dr. Lewis is actively involved in clinical research in national and international clinical trials in glaucoma therapy. He is on the Executive Board of the American Society of Cataract and Refractive Surgery as incoming President (April, 2014) and past president of the American Glaucoma Society (2000-02). Dr. Lewis is the medical editor emeritus of Glaucoma Today and on the editorial board of the Journal of Cataract and Refractive Surgery, Journal of Glaucoma, Video Journal of Ophthalmology, and Ocular Surgery News. Dr. Lewis received his doctorate in medicine from Northwestern University Medical School in Chicago in 1978. His ophthalmology training included a residency at the Department of Ophthalmology at the University of California, Davis, and a fellowship in glaucoma at the University Of Iowa Department Of Ophthalmology in Iowa City. He is a Diplomat of the American Board of Ophthalmology and the National Board of Medical Examiners. Dr. Lewis has published over eighty articles and book chapters focusing on glaucoma, ophthalmic surgery, and ophthalmic pharmacology.
About Aerie Pharmaceuticals
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company is preparing for two Phase 3 registration trials where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for Rhopressa™ (dosed once daily) compared to timolol (dosed twice daily). The Company is also currently executing a Phase 2b clinical trial where the primary efficacy endpoint is to demonstrate superiority of Roclatan™ to each of its components.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success, timing and cost of our ongoing clinical trials and anticipated Phase 3 clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect, to our product candidates; our estimates regarding anticipated capital requirements and our needs for additional financing; our expectations regarding the clinical effectiveness of our product candidates and results of our clinical trials; the potential advantages of our product candidates, including reduction of episcleral venous pressure (EVP) as an additional action; our ability to protect our proprietary technology and enforce our intellectual property rights; and our expectations related to the use of proceeds from our initial public offering. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on regulatory approvals and economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" in our final prospectus from our initial public offering which is on file with the Securities and Exchange Commission (SEC), and in the quarterly and annual reports that we file with the SEC. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.